EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Recent Releases
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Events & Presentations
Building value through innovation, dedicated to making a difference.
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_presentation.png)
![](sites/g/files/knoqqb89226/themes/site/nir_pid1014/dist/images/investor_icon_pdf.png)